logo

For the Inventor, By the Inventor

Raleigh, NC, United States of America

Liposcience, Inc.


USPTO Granted Patents = 35

% Expired Patents = 8.6



Trademarks = 5

Forward Citations = 226

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal James D Otvos (33 out of 41 patents)

silverMedal Irina Y Shalaurova (18 out of 21 patents)

bronzeMedal Elias J Jeyarajah (11 out of 12 patents)

4.  Dennis W Bennett (11 out of 14 patents)

5.  Justyna E Wolak-Dinsmore (10 out of 11 patents)

6.  Thomas M O'Connell (8 out of 8 patents)

7.  Steven P Matyus (7 out of 7 patents)

8.  David R Morgan (5 out of 5 patents)

9.  Stephen Markham (4 out of 4 patents)

10.  Bruce D Silberman (4 out of 4 patents)

11.  Donald R Deuel (4 out of 4 patents)

12.  Kelly Mercier (4 out of 4 patents)

13.  Stanley Leon Hazen (3 out of 59 patents)

14.  Stanley L Hazan (1 out of 1 patent)

15.  Russell Reeve (1 out of 1 patent)


Core Competencies:
NMR Technology
Metabolic Vulnerability
Diabetes Risk Evaluation
Cardiovascular Risk
HDL Particle Number
Biosample Analysis
Lipoprotein Insulin Resistance
TMAO Quantification
GlycA Biomarker
CHD Risk Stratification
Multiple-Marker Parameters
Personalized Risk Assessments

35 patents:

1. 12130295 - NMR system and methods for multi-parameter metabolic vulnerability index evaluations (2024-10-29),
2. 11990243 - Multiple-marker risk parameters predictive of conversion to diabetes (2024-05-21),
3. 11988679 - Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter (2024-05-21),
4. 11942187 - Methods, systems and computer programs for assessing CHD risk using adjusted HDL particle number measurements (2024-03-26),
5. 11782002 - NMR quantification of TMAO (2023-10-10),
6. 11710568 - Multi-parameter diabetes risk evaluations (2023-07-25),
7. 11703501 - CHD risk stratification evaluations for subjects with high levels of large HDL-P (2023-07-18),
8. 11231429 - Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter (2022-01-25),
9. 11156685 - NMR analyzers for clinical evaluation of biosamples (2021-10-26),
10. 11156621 - Multi-parameter metabolic vulnerability index evaluations (2021-10-26),
11. 11037683 - Multiple-marker risk parameters predictive of conversion to diabetes (2021-06-15),
12. 10852293 - NMR measurements of NMR biomarker GlycA (2020-12-01),
13. 10613044 - NMR quantification of TMAO (2020-04-07),
14. 10504610 - Methods, systems and computer programs for assessing CHD risk using adjusted HDL article number measurements (2019-12-10),
15. 10388414 - Multi-parameter diabetes risk evaluations (2019-08-20),
Liposcience, Inc. is a biotechnology company based in Raleigh, North Carolina, specializing in advanced diagnostic solutions. The organization focuses on developing innovative technologies for the analysis of lipoproteins and other biomarkers, aiming to enhance the understanding of cardiovascular health. Liposcience's research is pivotal in the field of personalized medicine, providing insights that assist healthcare professionals in making informed decisions regarding patient care and treatment strategies.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Liposcience, Inc.
35 Patents

#23 in Raleigh, NC

#230 in North Carolina

#9,740 in US

#19,148 in the World

Raleigh, NC (US)
Raleigh, NC, United States of America

Liposcience, Inc.

Forward Citations = 226

15 inventors:

goldMedal James D Otvos (33 out of 41 patents)

silverMedal Irina Y Shalaurova (18 out of 21 patents)

bronzeMedal Elias J Jeyarajah (11 out of 12 patents)

4.  Dennis W Bennett (11 out of 14 patents)

5.  Justyna E Wolak-Dinsmore (10 out of 11 patents)

Please report any incorrect information to [email protected]
Loading…